WallStreetZenWallStreetZen

NASDAQ: ACRS
Aclaris Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for ACRS

Based on 6 analysts offering 12 month price targets for Aclaris Therapeutics Inc

Min Forecast
$7.00+514.04%
Avg Forecast
$11.67+923.42%
Max Forecast
$20.00+1,654.39%

Should I buy or sell ACRS stock?

Based on 6 analysts offering ratings for Aclaris Therapeutics Inc.

Strong Buy
Strong Buy
3 analysts 50%
Buy
3 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although ACRS's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates ACRS as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their ACRS stock forecasts and price targets.

ACRS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-03-07
lockedlocked$00.00+00.00%2024-12-23
lockedlocked$00.00+00.00%2024-11-19
lockedlocked$00.00+00.00%2024-11-19
lockedlocked$00.00+00.00%2024-11-19
Piper Sandler
Bottom 5%
5
Strong BuyUpgrades$13.00+1,040.35%2024-11-18

1 of 1

Forecast return on equity

Is ACRS forecast to generate an efficient return?

Company
-59.66%
Industry
45.29%
Market
81.76%
ACRS's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ACRS forecast to generate an efficient return on assets?

Company
-42.12%
Industry
19.2%
ACRS is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ACRS earnings per share forecast

What is ACRS's earnings per share in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
-$0.71
Avg 2 year Forecast
-$0.73
Avg 3 year Forecast
-$0.85

ACRS revenue forecast

What is ACRS's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$17.3M-7.45%
Avg 2 year Forecast
$18.5M-1%
Avg 3 year Forecast
$29.6M+57.85%
ACRS's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

ACRS revenue growth forecast

How is ACRS forecast to perform vs Diagnostics & Research companies and vs the US market?

Company
13.26%
Industry
5.84%
Market
10.4%
ACRS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ACRS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ACRS vs Diagnostic & Research Stocks

TickerPricePrice TargetUp/downsideConsensus
ACRS$1.14$11.67+923.42%Strong Buy
SERA$3.40N/AN/A
OCX$2.84$4.42+55.53%Buy
FONR$12.25N/AN/A
XGN$4.49$7.50+67.04%Strong Buy
View Top Diagnostic & Research Stocks

Aclaris Therapeutics Stock Forecast FAQ

Is Aclaris Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: ACRS) stock is to Strong Buy ACRS stock.

Out of 6 analysts, 3 (50%) are recommending ACRS as a Strong Buy, 3 (50%) are recommending ACRS as a Buy, 0 (0%) are recommending ACRS as a Hold, 0 (0%) are recommending ACRS as a Sell, and 0 (0%) are recommending ACRS as a Strong Sell.

If you're new to stock investing, here's how to buy Aclaris Therapeutics stock.

What is ACRS's earnings growth forecast for 2025-2027?

(NASDAQ: ACRS) Aclaris Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Diagnostics & Research industry's average forecast earnings growth rate of 22.6%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.2%.

Aclaris Therapeutics's earnings in 2025 is -$132,065,000.On average, 5 Wall Street analysts forecast ACRS's earnings for 2025 to be -$77,054,038, with the lowest ACRS earnings forecast at -$123,027,456, and the highest ACRS earnings forecast at -$62,592,916. On average, 3 Wall Street analysts forecast ACRS's earnings for 2026 to be -$79,136,871, with the lowest ACRS earnings forecast at -$85,255,869, and the highest ACRS earnings forecast at -$72,305,610.

In 2027, ACRS is forecast to generate -$91,730,998 in earnings, with the lowest earnings forecast at -$99,285,315 and the highest earnings forecast at -$84,176,680.

What is ACRS's revenue growth forecast for 2025-2027?

(NASDAQ: ACRS) Aclaris Therapeutics's forecast annual revenue growth rate of 13.26% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 5.84%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.4%.

Aclaris Therapeutics's revenue in 2025 is $18,720,000.On average, 4 Wall Street analysts forecast ACRS's revenue for 2025 to be $1,869,693,574, with the lowest ACRS revenue forecast at $528,802,223, and the highest ACRS revenue forecast at $4,392,296,015. On average, 3 Wall Street analysts forecast ACRS's revenue for 2026 to be $2,000,059,510, with the lowest ACRS revenue forecast at $97,126,939, and the highest ACRS revenue forecast at $4,823,971,299.

In 2027, ACRS is forecast to generate $3,189,001,161 in revenue, with the lowest revenue forecast at $1,089,980,092 and the highest revenue forecast at $5,288,022,229.

What is ACRS's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: ACRS) forecast ROA is -42.12%, which is lower than the forecast US Diagnostics & Research industry average of 19.2%.

What is ACRS's Price Target?

According to 6 Wall Street analysts that have issued a 1 year ACRS price target, the average ACRS price target is $11.67, with the highest ACRS stock price forecast at $20.00 and the lowest ACRS stock price forecast at $7.00.

On average, Wall Street analysts predict that Aclaris Therapeutics's share price could reach $11.67 by Mar 7, 2026. The average Aclaris Therapeutics stock price prediction forecasts a potential upside of 923.42% from the current ACRS share price of $1.14.

What is ACRS's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: ACRS) Aclaris Therapeutics's current Earnings Per Share (EPS) is -$1.71. On average, analysts forecast that ACRS's EPS will be -$0.71 for 2025, with the lowest EPS forecast at -$1.14, and the highest EPS forecast at -$0.58. On average, analysts forecast that ACRS's EPS will be -$0.73 for 2026, with the lowest EPS forecast at -$0.79, and the highest EPS forecast at -$0.67. In 2027, ACRS's EPS is forecast to hit -$0.85 (min: -$0.92, max: -$0.78).

What is ACRS's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: ACRS) forecast ROE is -59.66%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.